Recombinant protein Several companies have evaluated administering recombinant<unk>  in clinical trials for type<unk>  diabetes, type 2 diabetes, amyotrophic lateral sclerosis, severe burn injury and myotonic muscular dystrophy. Results of clinical trials evaluating the efficacy of<unk>  in type<unk>  diabetes and type 2 diabetes showed reduction in hemoglobin A1C levels and daily<unk>  consumption. However the sponsor discontinued the program due to an exacerbation of diabetic retinopathy, coupled with a shift in corporate focus towards oncology. Two clinical studies of<unk>  for ALS were conducted and although one study demonstrated efficacy the second was equivocal, and the product was not submitted for approval to the FDA.
Insulin-like growth factor 1
Keratinocyte growth factor
Calcitonin gene-related peptide
Growth hormone
Bryostatin
Orexin
Neurotrophic factors
Hemopoietic growth factor